Buch, Englisch, 626 Seiten, Format (B × H): 178 mm x 254 mm, Gewicht: 1746 g
Buch, Englisch, 626 Seiten, Format (B × H): 178 mm x 254 mm, Gewicht: 1746 g
ISBN: 978-1-4822-1502-1
Verlag: Apple Academic Press Inc.
Edited by an expert editorial team from leading dermatology centers, this set consists of two books: Mild to Moderate Psoriasis, Third Edition and Moderate to Severe Psoriasis, Fourth Edition. Using a practical and problem-focused approach, these updated texts equip dermatologists, family practitioners, and internists with a state-of-the-art guide to the clinical management of all forms of psoriasis. The set provides up-to-date treatment strategies for optimum patient management.
Zielgruppe
Professional Reference
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Mild to Moderate Psoriasis, Third Edition: Introduction to Mild-to-Moderate Psoriasis. General Approach to Psoriasis Treatment. General Guidelines for Administration of Topical Agents in the Treatment of Mild-To-Moderate Psoriasis. Topical Corticosteroids. Vitamin D3 analogs. Fixed Dose Corticosteroid/Calcipotriene Combination Therapy. Topical Tazarotene. Topical Calcineurin Inhibitors. Treatment of Mild-To-Moderate Psoriasis with Coal Tar, Anthralin, Salicyclic Acid, and Lactic Acid. Phototherapy and Laser for the Treatment of Mild-To-Moderate Psoriasis. Topical Sequential Therapy of Psoriasis. Combination Therapy. Palmoplantar Psoriasis. Scalp Psoriasis. Inverse Psoriasis. Psoriasis of the Nails. Moderate to Severe Psoriasis, Fourth Edition: An Overview of Psoriasis. Evaluating Psoriasis in Patients. Topical Agents in the Treatment of Moderate to Severe Psoriasis. The Art and Practice of UVB Phototherapy and Laser for the Treatment of Moderate-to-Severe PSO. Systemic and Topical PUVA Therapy. Therapy of Moderate-To-Severe PSO with MTX. Systemic Retinoids. Cyclosporine in the treatment of severe pSO. Combination, Rotational, and Sequential Therapies. Pediatric Psoriasis. Psoriatic Arthritis. Etanercept for Treatment of Psoriasis. Adalimumab in the treatment of psoriasis. Infliximab in the treatment of PSO. New Agents: IL-17, JAK kinase. Ustekinumab. Current and Potential Applications of Pharmacogenetics and Pharmacogenomics in the Treatment of Pso. The Immunomodulatory/Immunosuppressive Classification System. Goeckerman and Ingram Day Treatment Program.
